TLR4 and malaria: A malaria vaccine with as little as 1 μg of the synthetic TLR4 agonist Glucopyranosyl Lipid Adjuvant (GLA) and 0.4 μg QS-21 in a liposomal formulation has been shown to be immunogenic in humans47.